BridgeMD
Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury
EU CTIS ID: 2025-523914-10-00
What this study is testing
To investigate the effect of sodium bicarbonate on major adverse kidney events at day 90
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult ≥ 18 years
- Critically ill patients (requiring treatment on an Intensive Care Unit or Intermediate Care Unit)
- Metabolic acidosis, defined as all of the following: a. Arterial pH ≤7.25 b. PaCO2 < 6.5kPa (<49 mmHg) c. Standard bicarbonate ≤20 mmol/L d. Standard Base Excess <-2
- AKI stage 2 or 3 of the KDIGO classification
- Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536/2014)
You likely can't join if
- Respiratory acidosis (acute or chronic)
- Symptomatic hypocalcaemia (Ionized calcium <1.05 mmol/L)
- Hypernatremia (plasma sodium >150 mmol/L)
- Severe hypokalemia (potassium <3.0 mmol/L)
- Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer
- Deemed unsuitable for KRT
See the full eligibility criteria
- Adult ≥ 18 years
- Critically ill patients (requiring treatment on an Intensive Care Unit or Intermediate Care Unit)
- Metabolic acidosis, defined as all of the following: a. Arterial pH ≤7.25 b. PaCO2 < 6.5kPa (<49 mmHg) c. Standard bicarbonate ≤20 mmol/L d. Standard Base Excess <-2
- AKI stage 2 or 3 of the KDIGO classification
- Written informed consent of the patient or legal representative or authorized representative or emergency inclusion (according to Article 35 EU-Regulation 536/2014)
- Respiratory acidosis (acute or chronic)
- Symptomatic hypocalcaemia (Ionized calcium <1.05 mmol/L)
- Hypernatremia (plasma sodium >150 mmol/L)
- Severe hypokalemia (potassium <3.0 mmol/L)
- Patients on KRT, or KRT immediately indicated and treating clinician(s) unwilling to defer
- Deemed unsuitable for KRT
- High output stoma/ileostomy
- Percutaneous biliary drainage
- End stage kidney failure defined as documented eGFR <15ml/min/1.73m2 prior to onset of this acute illness or end stage kidney disease (ESKD) on dialysi
- Known renal tubular acidosis
- Diabetic ketoacidosis
- High anion gap acid poisoning (e.g. polyethylene glycol (PEG), aspirin, methanol)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.